Regression of HIV-associated progressive encephalopathy of childhood during HAART.
HIV-associated progressive encephalopathy of childhood is characterized by impaired brain growth, decline in cognitive and neurobehavioral performances, and progressive motoric dysfunction The diagnosis is based on neurological examination, neuropsychological assessment and cerebral CT or MR imaging. While the importance of early use of antiretroviral combination therapy has been emphasized, limited data exist as to the effect of protease inhibitors in children with HIV-associated encephalopathy. We describe the effect of 3-drug antiretroviral combination therapy, including the protease inhibitor nelfinavir, in a 7-y-old girl with vertically acquired HIV infection and late onset progressive encephalopathy.
Rosenfeldt
V
V
Department of Paediatrics, Copenhagen University Hospital Hvidovre, Denmark.
Valerius
N H
NH
Paerregaard
A
A
D015526:AIDS Dementia Complex / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D019888:Nelfinavir / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019888:Nelfinavir